Ana Maria Waaga-Gasser

Prof. Ana Maria Waaga-Gasser


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
TGTanja Grimmig
Tanja Grimmig
RMRomana Moench
Romana Moench
JKJennifer Kreckel
Jennifer Kreckel
SHStephanie Haack
Stephanie Haack
FRFelix Rückert
Felix Rückert
AWAna Maria Waaga-Gasser
Ana Maria Waaga-Gasser
Toll like receptor (TLR) signaling has been suggested to play an important role in the inflammatory microenvironment of solid tumors and through this inflammation-mediated tumor growth. Here, we studied the role of tumor cells in their process of self-maintaining TLR expression independent of inflammatory cells and cytokine milieu for autoregulative tumor growth signaling in pancreatic cancer. We analyzed the expression of TLR2, -4, and -9 in primary human cancers and their impact on tumor growth via induced activation in several established pancreatic cancers. TLR-stimulated pancreatic cancer cells were specifically investigated for activated signaling pathways of VEGF/PDGF and anti-apoptotic Bcl-xL expression as well as tumor cell growth. The primary pancreatic cancers and cell lines expressed TLR2, -4, and -9. TLR-specific stimulation resulted in activated MAP-kinase signaling, most likely via autoregulative stimulation of demonstrated TLR-induced VEGF and PDGF expression. Moreover, TLR activation prompted the expression of Bcl-xL and has been demonstrated for the first time to induce tumor cell proliferation in pancreatic cancer. These findings strongly suggest that pancreatic cancer cells use specific Toll like receptor signaling to promote tumor cell proliferation and emphasize the particular role of TLR2, -4, and -9 in this autoregulative process of tumor cell activation and proliferation in pancreatic cancer.

8 September 2016 in Oncotarget
Verified
Journal Article
Open access
RMRomana Moench
Romana Moench
TGTanja Grimmig
Tanja Grimmig
VKVinicius Kannen
Vinicius Kannen
STSudipta Tripathi
Sudipta Tripathi
MFMarc Faber
Marc Faber
MGMartin Gasser
Martin Gasser
Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer

1 January 2017 in Cancer Growth and Metastasis
Verified
Journal Article
Open access
TGTanja Grimmig
Tanja Grimmig
EMEva-Maria Moll
Eva-Maria Moll
KKKerstin Kloos
Kerstin Kloos
RTRebecca Thumm
Rebecca Thumm
RMRomana Moench
Romana Moench
MGMartin Gasser
Martin Gasser
In patients with peritoneal carcinomatosis cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) represents a promising treatment strategy. Here, we studied the role of hyperthermic chemotherapy on heat shock protein (HSP) expression and induction of tumor cell death and survival. HSP27, HSP70, and HSP90 combined with effects on tumor cell proliferation and chemosensitivity were analyzed in human colon cancer. Hyperthermic chemotherapy resulted in significant HSP27/HSP70 and HSP90 gene/protein overexpression in analyzed HT-29/SW480/SW620 colon cancer cells and peritoneal metastases from patients displaying amplified expression of proliferation markers, proliferating cell nuclear antigen and antiapoptotic protein Bcl-xL. Moreover, functionally increased chemoresistance against 5-fluorouracil/mitomycin C and oxaliplatin after hyperthermic chemotherapy points to induced survival mechanisms in cancer cells. In conclusion, the results indicate that intracellular HSP-associated antiapoptotic and proliferative effects after hyperthermic chemotherapy negatively influence beneficial effects of hyperthermic chemotherapy-induced cell death. Therefore, blocking HSPs could be a promising strategy to further improve the rate of tumor cell death and outcome of patients undergoing HIPEC therapy.

6 November 2015 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CDCholpon S. Djuzenova
Cholpon S. Djuzenova
MZMarcus Zimmermann
Marcus Zimmermann
AKAstrid Katzer
Astrid Katzer
VFVanessa Fiedler
Vanessa Fiedler
Luitpold DistelLuitpold Distel
Luitpold Distel
Bülent PolatBülent Polat
Bülent Polat
The prognostic value of histone γ-H2AX and 53BP1 proteins to predict the radiotherapy (RT) outcome of patients with rectal carcinoma (RC) was evaluated in a prospective study. High expression of the constitutive histone γ-H2AX is indicative of defective DNA repair pathway and/or genomic instability, whereas 53BP1 (p53-binding protein 1) is a conserved checkpoint protein with properties of a DNA double-strand breaks sensor. Using fluorescence microscopy, we assessed spontaneous and radiation-induced foci of γ-H2AX and 53BP1 in peripheral blood mononuclear cells derived from unselected RC patients (n = 53) undergoing neoadjuvant chemo- and RT. Cells from apparently healthy donors (n = 12) served as references. The γ-H2AX assay of in vitro irradiated lymphocytes revealed significantly higher degree of DNA damage in the group of unselected RC patients with respect to the background, initial (0.5 Gy, 30 min) and residual (0.5 Gy and 2 Gy, 24 h post-radiation) damage compared to the control group. Likewise, the numbers of 53BP1 foci analyzed in the samples from 46 RC patients were significantly higher than in controls except for the background DNA damage. However, both markers were not able to predict tumor stage, gastrointestinal toxicity or tumor regression after curative RT. Interestingly, the mean baseline and induced DNA damage was found to be lower in the group of RC patients with tumor stage IV (n = 7) as compared with the stage III (n = 35). The difference, however, did not reach statistical significance, apparently, because of the limited number of patients. The study shows higher expression of γ-H2AX and 53BP1 foci in rectal cancer patients compared with healthy individuals. Yet the data in vitro were not predictive in regard to the radiotherapy outcome.

31 December 2010 in Clinical Immunology
Verified
Journal Article
Closed access
MGMartin Gasser
Martin Gasser
MGMartin Grimm
Martin Grimm
MKMia Kim
Mia Kim
ARAndreas Rosenwald
Andreas Rosenwald
CGChristoph Germer
Christoph Germer
AWAna Maria Waaga-Gasser
Ana Maria Waaga-Gasser

31 December 2010 in Clinical Immunology
Verified
Journal Article
Closed access
MGMartin Gasser
Martin Gasser
ITIgor Tsaur
Igor Tsaur
KLKai Lopau
Kai Lopau
CGChristoph Germer
Christoph Germer
ACAnil Chandraker
Anil Chandraker
AWAna Maria Waaga-Gasser
Ana Maria Waaga-Gasser